Changes in T lymphocyte subsets in peripheral blood of patients with middle-advanced cervical cancer before and after nimotuzumab combined with concurrent chemoradiotherapy

References

• Assad, D. X., et al., 2016. Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: a systematic review. Oncology Letters, 12 (5), 4107–4116.
   PubMed Web of Science ®Google Scholar
• Bizzarri, N., et al., 2021. Peritoneal HPV-DNA test in cervical cancer (PIONEER study): a proof of concept. International Journal of Cancer, 148 (5), 1197–1207.
   PubMed Web of Science ®Google Scholar
• Burmeister, C. A., et al., 2022. Cervical cancer therapies: current challenges and future perspectives. Tumour Virus Research, 13, 200238.
   PubMedGoogle Scholar
• Cascardi, E., et al., 2022. Association between cervical microbiota and HPV: could this be the key to complete cervical cancer eradication? Biology, 11 (8), 1114.
   PubMed Web of Science ®Google Scholar
• Castle, P. E., Einstein, M. H. and Sahasrabuddhe, V. V., 2021. Cervical cancer prevention and control in women living with human immunodeficiency virus. CA Cancer Journal for Clinicians, 71 (6), 505–526.
   PubMed Web of Science ®Google Scholar
• Cetina, L., et al., 2015. A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer. Cancer Biology & Therapy, 16, 684–689.
   PubMed Web of Science ®Google Scholar
• Chauhan, S. R. and Bharadwaj, M., 2018. Gearing up T-cell immunotherapy in cervical cancer. Current Problems in Cancer, 42, 175–188.
   PubMed Web of Science ®Google Scholar
• Chen, C., Liu, Y. and Cui, B., 2021. Effect of radiotherapy on T cell and PD-1/PD-L1 blocking therapy in tumor microenvironment. Human Vaccines & Immunotherapeutics, 17 (6), 1555–1567.
   PubMed Web of Science ®Google Scholar
• Chen, J., et al., 2021. Heterogeneity of IFN-mediated responses and tumor immunogenicity in patients with cervical cancer receiving concurrent chemoradiotherapy. Clinical Cancer Research, 27 (14), 3990–4002.
   PubMed Web of Science ®Google Scholar
• Chen, T., et al., 2020. T-lymphocyte subsets and Th1/Th2 cytokines in convalescent patients with Epstein-Barr virus-associated aplastic anemia. Hematology, 25 (1), 11–16.
   PubMed Web of Science ®Google Scholar
• Chen, W., et al., 2019. Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer. Cancer Management and Research, 11, 8157–8165.
   PubMed Web of Science ®Google Scholar
• Chen, Z., et al., 2013. The Th17/Treg balance and the expression of related cytokines in Uygur cervical cancer patients. Diagnostic Pathology, 8, 61.
   PubMed Web of Science ®Google Scholar
• Chraa, D., et al., 2019. T lymphocyte subsets in cancer immunity: Friends or foes. Journal of Leukocyte Biology, 105 (2), 243–255.
   PubMed Web of Science ®Google Scholar
• Cohen, P. A., et al., 2019. Cervical cancer. Lancet, 393, 169–182.
   PubMed Web of Science ®Google Scholar
• Crowley, F. J., O'Cearbhaill, R. E. and Collins, D. C., 2021. Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer. Cancer Treatment Reviews, 98, 102225.
   PubMed Web of Science ®Google Scholar
• Das, D., et al., 2018. An altered ratio of CD4+ And CD8+ T lymphocytes in cervical cancer tissues and peripheral blood – a prognostic clue? Asian Pacific Journal of Cancer Prevention, 19 (2), 471–478.
   PubMedGoogle Scholar
• de Melo, A. C., et al., 2016. A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I. Cancer Chemotherapy and Pharmacology, 78 (1), 101–109.
   PubMed Web of Science ®Google Scholar
• Eskander, R. N. and Tewari, K. S., 2014. Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. Journal of Gynecologic Oncology, 25 (3), 249–259.
   PubMed Web of Science ®Google Scholar
• Frenel, J. S., et al., 2017. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. Journal of Clinical Oncology, 35 (36), 4035–4041.
   PubMed Web of Science ®Google Scholar
• Gomes, F. G., et al., 2021. Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications. Brazilian Journal of Medical and Biological Research, 54 (6), e10754.
   PubMed Web of Science ®Google Scholar
• Gopu, P., et al., 2021. Updates on systemic therapy for cervical cancer. Indian Journal of Medical Research, 154 (2), 293–302.
   PubMed Web of Science ®Google Scholar
• Hou, M. M., et al., 2014. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: a phase I clinical experience. Oncotarget, 5 (22), 11168–11179.
   PubMedGoogle Scholar
• Li, R., et al., 2021. The dynamic alternation of local and systemic tumor immune microenvironment during concurrent chemoradiotherapy of cervical cancer: a prospective clinical trial. International Journal of Radiation Oncology Biology Physics, 110 (5), 1432–1441.
   PubMed Web of Science ®Google Scholar
• Liu, Y., An, Q. and Zhao, X., 2020. A pan-HER-targeted approach for recurrent or late-stage cervical cancer therapy: mechanisms, recent advances, and clinical prospects. European Review for Medical and Pharmacological Sciences, 24 (8), 4123–4131.
   PubMed Web of Science ®Google Scholar
• Matsuzaki, S., et al., 2020. Management of stage IIB cervical cancer: an overview of the current evidence. Current Oncology Reports, 22 (3), 28.
   PubMed Web of Science ®Google Scholar
• Mazorra, Z., et al., 2018. Nimotuzumab: beyond the EGFR signaling cascade inhibition. Seminars in Oncology, 45 (1–2), 18–26.
   PubMed Web of Science ®Google Scholar
• Muthusami, S., et al., 2022. A review on the role of epidermal growth factor signaling in the development, progression and treatment of cervical cancer. International Journal of Biological Macromolecules, 194, 179–187.
   PubMed Web of Science ®Google Scholar
• Naga Ch, P., et al., 2018. The management of locally advanced cervical cancer. Current Opinion in Oncology, 30 (5), 323–329.
   PubMed Web of Science ®Google Scholar
• Ohno, A., et al., 2020. Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy. Gynecologic Oncology, 159 (2), 329–334.
   PubMed Web of Science ®Google Scholar
• Okunade, K. S., 2020. Human papillomavirus and cervical cancer. Journal of Obstetrics and Gynaecology, 40 (5), 602–608.
   PubMed Web of Science ®Google Scholar
• Pimple, S. A. and Mishra, G. A., 2019. Global strategies for cervical cancer prevention and screening. Minerva Ginecologica, 71 (4), 313–320.
   PubMed Web of Science ®Google Scholar
• Sacks, D., et al., 2018. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. International Journal of Stroke, 13 (6), 612–632.
   PubMed Web of Science ®Google Scholar
• Schrevel, M., et al., 2017. Autocrine expression of the epidermal growth factor receptor ligand heparin-binding EGF-like growth factor in cervical cancer. International Journal of Oncology, 50 (6), 1947–1954.
   PubMed Web of Science ®Google Scholar
• Shah, W., et al., 2011. A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cellular & Molecular Immunology, 8 (1), 59–66.
   PubMed Web of Science ®Google Scholar
• Shi, K., et al., 2022. Emerging strategies to overcome resistance to third-generation EGFR inhibitors. Journal of Hematology & Oncology, 15 (1) 94.
   PubMed Web of Science ®Google Scholar
• Sung, H., et al., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer Journal for Clinicians, 71, 209–249.
   PubMed Web of Science ®Google Scholar
• Teng, F., et al., 2023. Changes of T lymphocyte subsets in peripheral blood of patients with intermediate and advanced cervical cancer before and after nimotuzumab combined with chemoradiotherapy. International Archives of Allergy and Immunology, 184 (1), 85–97.
   PubMed Web of Science ®Google Scholar
• Valenti, G., et al., 2017. Tumor markers of uterine cervical cancer: a new scenario to guide surgical practice? Updates in Surgery, 69 (4), 441–449.
   PubMed Web of Science ®Google Scholar
• Vizzielli, G., et al., 2021. Is a vaginectomy enough or is a pelvic exenteration always required for surgical treatment of recurrent cervical cancer? A propensity-matched study. Annals of Surgical Oncology, 28 (6), 3281–3290.
   PubMed Web of Science ®Google Scholar
• Zhang, L., et al., 2020. A review of the research progress in T-lymphocyte immunity and cervical cancer. Translational Cancer Research, 9, 2026–2036.
   PubMed Web of Science ®Google Scholar
• Zhao, Y., Shao, Q. and Peng, G., 2020. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. Cellular & Molecular Immunology, 17 (1), 27–35.
   PubMed Web of Science ®Google Scholar